glp 1 and parkinson's Repurposing GLP-1 Receptor Agonists for Disease: Current Evidence Future Opportunities | Pharmaceutical Medicine Glucagon-like peptide-1 (GLP-1) receptor agonists

Combination therapy with SGLT2 inhibitors + GLP-1 RAs may reduce cardiorenal risk and CV & all-cause mortality in T2D vs SGLT22 inhibitor and GLP-1 RA monotherapy

Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88

Consult our Seattle clinic for safe treatment

Sherry Shen, MD, shares retrospective data on how GLP-1s influence overall survival and safety outcomes among patients with breast cancer.

Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family implicated in the control of appetite and satiety

No fillers